Replies to post #371993 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I do not have handy the new primary measure as updated, if someone has it (please reply), but I doubt it started from a different date of measure than the old one, which is below:


https://clinicaltrials.gov/ct2/show/NCT00045968

“The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients. [ Time Frame: Time to tumor progression or death ]”

From ExW:

“5 of 6 were randomized post chemo-rad. 1 was in the middle of chemo-rad. All counted OS from, randomization. ATL (and dozens other) argue that the NWBO should compare their post surgery numbers to those post randomization numbers.”

Am I missing something?